These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2839612

  • 1. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
    Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA.
    J Med Virol; 1988 Jun; 25(2):189-95. PubMed ID: 2839612
    [Abstract] [Full Text] [Related]

  • 2. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ.
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [Abstract] [Full Text] [Related]

  • 3. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
    Morgan AJ, Finerty S, Lovgren K, Scullion FT, Morein B.
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():2093-6. PubMed ID: 2841417
    [Abstract] [Full Text] [Related]

  • 4. Vaccination against Epstein-Barr virus: current progress and future strategies.
    Epstein MA.
    Lancet; 1986 Jun 21; 1(8495):1425-7. PubMed ID: 2872525
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus vaccines.
    Morgan AJ.
    Vaccine; 1992 Jun 21; 10(9):563-71. PubMed ID: 1323899
    [Abstract] [Full Text] [Related]

  • 6. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours.
    Epstein MA.
    Proc R Soc Lond B Biol Sci; 1984 Mar 22; 221(1222):1-20. PubMed ID: 6144103
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Latent Epstein-Barr virus infection in cottontop tamarins. A possible model for Epstein-Barr virus infection in humans.
    Niedobitek G, Agathanggelou A, Finerty S, Tierney R, Watkins P, Jones EL, Morgan A, Young LS, Rooney N.
    Am J Pathol; 1994 Oct 22; 145(4):969-78. PubMed ID: 7943186
    [Abstract] [Full Text] [Related]

  • 11. Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.
    Mackett M, Cox C, Pepper SD, Lees JF, Naylor BA, Wedderburn N, Arrand JR.
    J Med Virol; 1996 Nov 22; 50(3):263-71. PubMed ID: 8923292
    [Abstract] [Full Text] [Related]

  • 12. Implications of a vaccine for the prevention of Epstein-Barr virus infection: ethical and logistic considerations.
    Epstein MA.
    Cancer Res; 1976 Feb 22; 36(2 pt 2):711-4. PubMed ID: 175931
    [Abstract] [Full Text] [Related]

  • 13. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge.
    Cox C, Naylor BA, Mackett M, Arrand JR, Griffin BE, Wedderburn N.
    J Med Virol; 1998 Aug 22; 55(4):255-61. PubMed ID: 9661832
    [Abstract] [Full Text] [Related]

  • 14. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.
    Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ.
    Vaccine; 1999 Mar 05; 17(9-10):1282-90. PubMed ID: 10195641
    [Abstract] [Full Text] [Related]

  • 15. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.
    Epstein MA, Randle BJ, Finerty S, Kirkwood JK.
    Clin Exp Immunol; 1986 Mar 05; 63(3):485-90. PubMed ID: 3011324
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ.
    J Exp Med; 1992 Jul 01; 176(1):169-76. PubMed ID: 1377222
    [Abstract] [Full Text] [Related]

  • 18. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.
    Morgan AJ, Epstein MA, North JR.
    J Med Virol; 1984 Jul 01; 13(3):281-92. PubMed ID: 6327902
    [Abstract] [Full Text] [Related]

  • 19. Enhanced expression of the Epstein-Barr virus latent membrane protein by a recombinant vaccinia virus.
    Stewart JP, Hampson IN, Heinrich HW, Mackett M, Arrand JR.
    J Gen Virol; 1989 May 01; 70 ( Pt 5)():1231-7. PubMed ID: 2543776
    [Abstract] [Full Text] [Related]

  • 20. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY, Rowe M, Morgan AJ, Sam CK, Prasad U, Dang H, Zeng Y, Rickinson AB.
    Int J Cancer; 1991 Apr 22; 48(1):45-50. PubMed ID: 1850382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.